Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS‐CoV‐2 induced inflammatory syndrome by utilization of the interleukin‐6 receptor antagonist (IL‐6Ra) tocilizumab.